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the CE of OAB treatments isn’t this simple, however, and
further research is needed to assess changes in resource
consumption due to treatment.
PRK6
EVALUATING THE COST OF LONG-ACTING
TREATMENTS FOR OVERACTIVE BLADDER
Becker RV1, Noe LL1, Chen DM1,Williamson TE2
1Ovation Research Group, Highland Park, IL, USA; 2Pharmacia,
Peapack, NJ, USA
OBJECTIVES: To compare the estimated ﬁrst-line treat-
ment costs of extended-release tolterodine versus con-
trolled-release oxybutynin in patients with overactive
bladder patients (OAB). METHODS: Data from a 
randomized clinical trial (Curr Med Res Opin 2002;
18:177–184), showing greater improvement in bladder
condition for patients taking extended-release tolterodine
compared to controlled-release oxybutynin (70% vs.
60% in all patients, 75% vs. 54% in patients with prior
therapy, and 69% vs. 61% in treatment naïve patients),
was used to conduct the analyses. The analysis input trial
outcomes into an existing decision analysis model that
had shown extended-release tolterodine was 6.3% less
expensive than controlled-release oxybutynin in terms of
the cost of treatment. Analyses were constructed from the
payer perspective; all costs are given in 2000 U.S. dollars.
RESULTS: The decision analysis model yielded results
that ranged between a 5.7% and 7.0% total cost of 
treatment advantage for extended-release tolterodine in
the treatment of all patients. This cost advantage 
was 5.1%–6.3% for treatment-naïve patients and
8.9%–10.8% for previously treated patients. The varia-
tion in the results depended on the model timeframe
chosen (12, 14, or 16 weeks). Sensitivity analyses showed
these results to be stable. CONCLUSIONS: Results from
these analyses conﬁrm earlier studies that, for patients
with OAB and initiating long-acting pharmacologic
therapy in the primary care setting, treatment with
extended-release tolterodine is less costly than treatment
with controlled-release oxybutynin. Additional studies
directly comparing these treatment alternatives are
needed to further conﬁrm these results.
URINARY & KIDNEY DISEASES/DISORDERS—
Quality of Life
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OBJECTIVES: Since satisfaction for telemedicine is ill-
deﬁned (Mair, 2000) and no standard measurement tool
is available, we developed a self-administered Question-
naire of the Satisfaction for Telemedicine (QueST).
METHODS: Domains of satisfaction were: 1) global 
satisfaction; 2) user-friendliness; 3) relationship with the
medical center; 4) coping; 5) everyday life; 6) expectations
about telemedicine; and 7) detailed judgment. Answers
were provided through a 4–5 degrees Likert scale; the
overall score was standardized to a maximum value of
100. After a probe technique, the ﬁnal QueST was admin-
istered to 26 patients on telemonitoring (transmission 
of subjective/objective data to an automatic call center 
or web server) for peritoneal dialysis or heart failure.
RESULTS: Mean age of the patients was 57.3 years
(range 43–74); 81% were males. Electronic devices 
(cellular phone or teletext) were daily used by 73% of the
patients, but computer by only 34% of them. Mean sat-
isfaction score was 72 (48–91): 29% of the patients were
highly satisﬁed with telemedicine either by considering
those with an overall score >= 80 or by assessing the
answer in the ﬁrst domain. However, a detailed elicita-
tion of patients judgement on telemedicine showed that
60% of them were very satisﬁed with it. Some users
(24%) declared to have some practical difﬁculties with
telemedicine but 88% of them expected a future beneﬁt
from telemedicine. Both the relations with the referral
center, quality of daily life and coping ability improved
during the period on telemedicine in 73%, 77%, 81% of
the patients, respectively. Willingness to pay for one year
of telemedicine was on average €81: 22% of the patients
were willing to pay for more than €90. CONCLUSIONS:
Acceptability of telemedicine is high and its impact over
the perceived quality of care is relevant. Nevertheless,
patients are willing to have this service included into their
usual health care with no or little extra costs. From the
patients perspective, telemedicine should be implemented
by the National Health Care System.
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HEMODIALYSIS (CHD)
Procaccini DA,Avanzi C, dell’Aquila R, Montemurno C,
Spada S
Civil Hospital “Teresa Masselli-Mascia”, San Severo, Foggia, Italy
OBJECTIVE: To evaluate the role of treatment approach
(CHD or CAPD) on the self-perception of QoL in uremic
patients. Cross-sectional matched pair study of CHD 
and CAPD subjects. METHODS: Sixty-two matched
pairs of patients (30M and 32F), median age 59 years
were studied. The CHD and CAPD groups were similar
for demographic and social variables. Higher percentage
of patients with diuresis >500ml/die and hypertension
were registred in CAPD patients. Nutritional Status was
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evaluated by Subjective Global Assessment (SGA). The
comorbidity of each patient was stratiﬁed by Index of Co-
Existent Disease (ICED). The MOS-Short Form 36 ques-
tionnaire was ﬁlled at home by patients to evaluate their
HRQoL. The eight multi-items scales, General Health
(GH), Role Physical (RP), Physical Function (PF), Role
Emotional (RE), Social Function (SF), Bodily Pain (BP),
Emotional Well-Being (EW-B), Energy/Fatigue (EF) were
summarized into two scores: Physical Component Score
(PCS), Mental Component Score (MCS).The scores were
expressed as median value. U-Mann Withney test was
used to compare the scores of the eight domains measured
by SF-36. QoL correlates were investigated with a series
of logistic regression analyses, where questionnaire
scores, dychotomised using the median value as cut-off,
were the depend variables. Results are thus expressed in
terms of Odds Ratio. RESULTS: The patients on CAPD
had a better, but not statistically signiﬁcant, self-percep-
tion of GH, SFand BP. The scores of the other domains
were signiﬁcantly better in CAPD than in CHD patients
(RP: 37vs37p < 0.02; PF: 75vs20p < 0.001; RE: 83vs20p
< 0.0002; EWB: 50vs45p < 0.0001; EF: 64vs52p < 0.01;
PCS: 40vs36p < 0.05; MCS: 43vs39 p < 0.05). Among
clinical correlates, female sex (OR: 3.34–95% CI:
1.12–9.03 p < 0.002), age > 58 years (OR: 3.81–95% 
CI -1.33–10.9 p < 0.01), SGA ≥ 1 (OR: 5.6–95% CI:
1.8–17.5 p < 0.001) high comorbidity (OR: 2.25–95%
CI: 1.5–13.4 p < 0.005) were signiﬁcantly associated 
to lower values of PCS. MCS was lower in patients 
with diuresis <500ml/die. CONCLUSIONS: Patients on
CAPD had a better self-perception of QoL until signiﬁ-
cant diuresis was manteined.
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OBJECTIVE: The degree of severity of the undesirable
mictional problems caused by BPH is assessed according
to the scores obtained in the acknowledged and validated
IPSS questionnaire. METHOD: In accordance with 
the WHO recommendations, the IPSS was proposed to
patients (n = 189) in the form of a self-questionnaire with
the aim of analyzing the obstruction and irritation scores
for the patients suffering from a recently diagnosed BPH
and treated with Serenoa Repens. RESULTS: The IPSS
obstruction score was respectively 6.7 (3.8) and 5.9 (3.5)
upon patient inclusion and after six months. This noted
difference is statistically signiﬁcant (p < 0.0001). The IPSS
irritation score was respectively 5.5 (2.6) and 4.5 (2.3)
upon patient inclusion and after six months. This dif-
ference is here statistically signiﬁcant with p < 0.0001.
CONCLUSION: Treatment by ﬁrst intention with
Serenoa Repens thus showed a signiﬁcant improvement
as demonstrated by both the obstruction and irritation
scores.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH have been found in 20 to 25% of the male popu-
lation over 50 years old. This condition can thus be 
considered as a public health problem that offers many
aspects in terms of diagnosis, therapeutics or economics.
METHOD: Within the framework of a follow-up cohort
study, a patient population suffering from a recently diag-
nosed BPH and treated with Serenoa repens (n = 158) was
asked to ﬁll in questionnaires SF12 and SPI upon inclu-
sion and 6 months later. RESULTS: When looking at the
SF-12, the results were organized in 2 types of scores: 
psychological (MCS-12) and physical (PCS-12). The SF12
scores upon patient inclusion were: PCS-12 = 41.7 and
MCS-12 = 46.5. The SF12 scores after 6 months were:
PCS-12 = 45.4 and MCS-12 = 46.9. These results bring
out a signiﬁcant improvement in the physical dimension
of the SF-12 (p < 0.0001). The SPI score upon patient
inclusion was 12.6 and reached 10.8 after 6 months of
treatment. This improvement is statistically signiﬁcant 
(p < 0.0001). CONCLUSION: Treatment by ﬁrst inten-
tion with Serenoa repens thus showed a signiﬁcant
improvement as demonstrated by the 2 validated scales,
SF12 and SPI.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH—benign prostatic hypertrophy—have been found
in 20 to 25% of the male population over 50 years old.
This condition can thus be considered as a public health
problem that offers many aspects in terms of diagnosis,
therapeutics or economics. METHOD: Using a follow-up
cohort study, we isolated two groups presenting a recently
diagnosed BPH: the ﬁrst patient population was kept
under medical supervision (n = 101) versus a second
patient population undergoing treatment with Serenoa
Repens (n = 112). RESULTS: For the patients under
medical supervision, the IPSS score was respectively 11.8
(5.7) and 10.9 (6.7) upon patient inclusion and after 6
months. This difference is not statistically signiﬁcant.
However, for the patients treated with Serenoa Repens,
